

Sudhir Tauro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5859028/publications.pdf>

Version: 2024-02-01

27
papers

5,278
citations

932766

10
h-index

610482

24
g-index

27
all docs

27
docs citations

27
times ranked

5952
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. <i>Blood</i> , 2012, 120, 2454-2465.	0.6	2,458
2	Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> , 2013, 122, 3616-3627.	0.6	1,562
3	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. <i>Blood</i> , 2011, 118, 6239-6246.	0.6	457
4	Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo. <i>Cancer Cell</i> , 2014, 25, 794-808.	7.7	272
5	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. <i>Leukemia</i> , 2019, 33, 1747-1758.	3.3	195
6	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. <i>Blood</i> , 2020, 136, 157-170.	0.6	195
7	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016, 128, 2096-2097.	0.6	46
8	Telomere length is an independent prognostic marker in MDS but not in de novo AML. <i>British Journal of Haematology</i> , 2017, 178, 240-249.	1.2	21
9	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <i>Leukemia Research</i> , 2018, 73, 51-57.	0.4	20
10	Predicted costs of iron chelators in myelodysplastic syndromes: A 10-year analysis based on actual prevalence and red cell transfusion rates. <i>American Journal of Hematology</i> , 2011, 86, 406-410.	2.0	14
11	Dose-intensified treatment of Burkitt lymphoma and B-cell lymphoma unclassifiable, (with features) Tj ETQq1 1 0.784314 rgBT / Over	2.0	7
12	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. <i>Blood</i> , 2014, 124, 532-532.	0.6	6
13	Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2016, 174, 227-234.	1.2	5
14	Azacitidine eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study. <i>British Journal of Haematology</i> , 2013, 161, 280-282.	1.2	4
15	An unusual extranodal T-cell non-Hodgkin lymphoma. <i>Lancet</i> , The, 2016, 388, 1127-1128.	6.3	3
16	Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts. <i>Blood</i> , 2011, 118, 3-3.	0.6	3
17	The long shadow of socioeconomic deprivation over the modern management of acute myeloid leukemia: time to unravel the challenges. <i>Blood Cancer Journal</i> , 2021, 11, 141.	2.8	2
18	Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age. <i>Blood</i> , 2013, 122, 1544-1544.	0.6	2

#	ARTICLE	IF	CITATIONS
19	The diversity of neutrophil inclusion bodies in fulminant sepsis. British Journal of Haematology, 2018, 182, 317-317.	1.2	1
20	Immunosuppression in hematological cancer patients with Covid-19 – Uncomplicated infections but delayed viral clearance?. Leukemia Research, 2020, 96, 106407.	0.4	1
21	An exemplar population-based study to predict up-take of non-intensive therapies in acute myeloid leukaemia. Leukemia Research, 2020, 92, 106348.	0.4	1
22	The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients. Blood, 2013, 122, LBA-2-LBA-2.	0.6	1
23	High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic. Blood, 2012, 120, LBA-5-LBA-5.	0.6	1
24	A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia. British Journal of Haematology, 2022, 196, 1337-1343.	1.2	1
25	Chest pain and small red cells: size does matter. Lancet, The, 2009, 374, 426.	6.3	0
26	Erythematous Macular Eruption in an Older Woman. JAMA Oncology, 2019, 5, 565.	3.4	0
27	Duration of First Remission in Diffuse Large B-Cell Lymphoma (DLBCL) Define Groups of Patients with Different Overall Survival Which Cannot Be Entirely Distinguished by Clinical Features or IPI at Diagnosis: a Prospective Population Based Study of the Scotland and Newcastle Lymphoma Group. Blood, 2008, 112, 2604-2604.	0.6	0